Caraway Therapeutics is a technology company.
Caraway Therapeutics has raised $23.0M across 1 funding round.
Caraway Therapeutics has raised $23.0M in total across 1 funding round.
Caraway Therapeutics is a preclinical biopharmaceutical company developing small-molecule therapeutics that modulate lysosomal function to activate cellular recycling processes, targeting genetically defined neurodegenerative diseases like ALS and Parkinson's, as well as rare diseases.[1][2][3] It serves patients with these conditions by addressing toxic protein accumulation and defective cellular components through precision medicine, solving the core problem of impaired cellular clearance that drives disease progression; the company demonstrated strong preclinical progress, attracting top investors like SV Health Investors, AbbVie Ventures, and Amgen Ventures before its acquisition by Merck (MSD outside the US/Canada) in a deal valued up to $610 million announced in November 2023.[1][3][4]
Caraway Therapeutics, based in Cambridge, MA with operations in Boston and London, UK, emerged as a leader in lysosomal modulation science, backed by venture funds focused on neurodegeneration such as SV Health Investors' Dementia Discovery Fund.[1][2][3] While specific founders are not detailed in available sources, CEO Martin D. Williams led the team, emphasizing a mission to develop disease-modifying therapies; the idea stemmed from insights into cellular recycling pathways like autophagy and mitophagy to restore equilibrium in diseased cells.[2][3] Early traction included building a robust preclinical pipeline with candidates targeting TMEM175 for ALS, ATP13A2 for Parkinson's (later discontinued), and TRPML1 agonists for rare diseases, culminating in Merck's acquisition as a pivotal validation of their progress.[1][2][4]
Caraway rode the trend of precision medicine in neurodegeneration, where lysosomal dysfunction is increasingly recognized as a driver in diseases like ALS and Parkinson's amid aging populations and genetic insights.[1][2] Timing aligned with surging investment in cellular recycling therapies (autophagy/mitophagy modulation), fueled by market forces like unmet needs in disease-modifying treatments and big pharma's push into rare/genetic diseases—Merck's acquisition underscores this, integrating Caraway's tech into a premier R&D engine to accelerate global health solutions.[1][3][4] It influences the ecosystem by validating lysosomal targets, potentially inspiring similar biotechs and enhancing Merck's neurodegeneration portfolio.
Post-acquisition, Caraway's pipeline will advance within Merck's infrastructure, prioritizing lysosomal modulators toward clinical stages for ALS, Parkinson's, and rare diseases, with milestones tied to development progress.[1][4] Trends like AI-driven target discovery and combo therapies for neurodegeneration will shape its trajectory, amplifying impact as Merck leverages its scale for global trials. This positions Caraway's innovations to evolve from preclinical promise to potential therapies, reinforcing its role in transforming genetically defined disease treatment.
Caraway Therapeutics has raised $23.0M in total across 1 funding round.
Caraway Therapeutics's investors include SV Health Investors, AbbVie Ventures, Atlas Venture, Krishna Yeshwant, RA Capital, SR One.
Caraway Therapeutics has raised $23.0M across 1 funding round. Most recently, it raised $23.0M Series A in October 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2018 | $23.0M Series A | SV Health Investors, AbbVie Ventures, Atlas Venture, Krishna Yeshwant, RA Capital, SR One |